OverviewChartNewsTraderScreen

Soc. Generale Knock-Out MRK/  DE000SF93NP2  /

Frankfurt Zert./SG
2024-04-19  9:00:50 PM Chg.+0.060 Bid9:06:45 PM Ask9:06:45 PM Underlying Strike price Expiration date Option type
4.080EUR +1.49% 4.090
Bid Size: 60,000		 4.100
Ask Size: 60,000		 Merck and Co Inc 82.6112 USD 2078-12-31 Call
GlobeNewswire 04-18 The New York Academy of Medicine Announces New Board of Trustee Members
GlobeNewswire 04-15 IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness
GlobeNewswire 04-09 IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer...
GlobeNewswire 04-05 IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer
GlobeNewswire 04-03 TOMI Environmental Solutions Receives Gold Safety Award from Highwire
GlobeNewswire 04-02 Vaccinex Reports 2023 Financial Results and Provides Corporate Update
TeleTrader 03-27 US opens higher after more housing data
GlobeNewswire 03-18 Aspira Women’s Health Expands Senior Leadership Team with the Addition of Sandra Milligan, M.D., J.D...
GlobeNewswire 03-15 American Kidney Fund Announces 2024 Class of Corporate Members Providing Support in the Fight Agains...
GlobeNewswire 03-06 IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Can...
GlobeNewswire 03-05 IO Biotech Announces 2023 Fourth-Quarter and Year-End Results
GlobeNewswire 03-05 Sandoz announces nominations to the Board of Directors and leadership change
GlobeNewswire 02-26 IO Biotech to Present at 44th Annual Cowen Health Care Conference
GlobeNewswire 02-07 Alleo Labs Announces Publication on the Use of Artificial Intelligence in Neuroscience Drug Discover...
TeleTrader 02-01 US opens higher, recovers from Wednesday's losses
TeleTrader 02-01 Merck's Q4 sales up 6% to $14.6B
TeleTrader 01-27 J&J, Merck CEOs to testify before Senate on drug prices
GlobeNewswire 01-09 C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted ...
GlobeNewswire 2023-12-21 IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial
GlobeNewswire 2023-12-07 Compass Pathways appoints Teri Loxam as Chief Financial Officer
GlobeNewswire 2023-12-04 Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule
GlobeNewswire 2023-11-15 Mural Oncology Launches to Advance Pipeline of Novel Engineered Cytokine Immunotherapies
GlobeNewswire 2023-11-13 IO Biotech Announces 2023 Third Quarter Results
GlobeNewswire 2023-11-13 Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
GlobeNewswire 2023-11-10 IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma